News Conference News TCT 2025 Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2 Todd Neale November 03, 2025
News Conference News TCT 2021 EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI Michael O'Riordan October 15, 2021
News Daily News DCB in Diabetes Show Promising Long-term Outcomes: BASKET-SMALL 2 L.A. McKeown August 16, 2021
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2018 Shelley Wood October 02, 2018
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Features Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más Shelley Wood December 30, 2016
News Daily News Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label? Yael L. Maxwell December 23, 2016
News Daily News Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis Michael O'Riordan April 25, 2016
News Daily News Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes Michael O'Riordan April 25, 2016
News Conference News RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority August 31, 2011
News Daily News No Apparent Advantage for Everolimus vs. Paclitaxel Stents in Diabetic Patients L.A. McKeown August 19, 2011
News Daily News ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics Caitlin E. Cox August 03, 2011